Abstract IA26: Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums

Abstract

Abstract SARS-CoV-2 and the resulting disease, COVID-19, has led to a global pandemic with broad impact on the delivery of medical care. Cancer patients may be especially vulnerable to both infection and adverse outcomes from COVID due to a number of factors including advanced age, immunosuppression from disease and/or anticancer therapy, and heightened interaction with the medical system. Several cohort studies have been launched to more fully understand risk factors for death and other adverse outcomes in patients with active or remote cancer. CCC-19 is a cohort study involving more than 100 institutions that enter data into a REDCaP database regarding patient demographics, cancer type and treatment details, and outcome of COVID infection. All patients have documented SARS-CoV-2 PCR positive and/or clinical symptoms consistent with COVID, in addition to an ongoing or past history of invasive malignancy. The initial analysis of this cohort study (n=928; Kuderer et al., Lancet 2020) demonstrated a 13% mortality rate and revealed several factors associated with an increased mortality including advanced age, male gender, greater number of comorbidities, worse ECOG performance status, and progressive cancer. Recent cancer surgery and receipt of cytotoxic or other systemic anticancer therapy was not associated with worse outcome, although small patient numbers in some subsets precluded definitive conclusions. At present, there are approximately 3,000 patients entered into this database and updated analyses will be presented. In addition to this effort, a number of other societies have created similar databases including ASH, ASCO, and ESMO. These complementary efforts will allow a global assessment of the impact of COVID on cancer patients including mortality and adverse outcomes in addition to cancer-specific outcomes. Last, the NCI COVID-19 in Cancer Patients Study (NCCAPS) is a prospective study in patients with active cancer and recent SARS-CoV-2 infection. This 2,000-patient study is open to accrual and will prospectively define both the impact of COVID on cancer and also cancer status and treatment on COVID outcome. In addition, biospecimen collection in this study will examine genetic predisposition, cytokine and coagulopathic parameters, and serologic outcomes. Collectively, these retrospective and prospective efforts will enable a more granular understanding of COVID in cancer patients to enable both appropriate cancer care delivery and improvement in outcomes in cancer patients with COVID infection. Citation Format: Brian I. Rini, (on behalf of the CCC-19 Consortium). Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr IA26.